Your prediction
ALS Ltd Stock
The price for the ALS Ltd stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.840%).
Pros and Cons of ALS Ltd in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ALS Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ALS Ltd | -0.840% | -3.279% | -4.065% | 28.261% | 31.844% | 56.291% | 95.041% |
| Seek Ltd | -0.780% | -5.185% | -11.724% | -13.514% | -5.882% | -8.571% | -21.951% |
| Downer EDI Ltd | -0.450% | 0.917% | 1.852% | 37.500% | 41.026% | 86.441% | 36.646% |
| Insperity Inc. | 5.190% | 7.285% | 10.204% | -58.987% | -55.310% | -70.811% | -53.714% |
News
North American Niobium and Critical Minerals Corp. Completes Phase 1 Fall Prospecting Program; Carbonatite and Pegmatite Targets Identified Across Québec Properties
- Completion of Fall 2025 Prospecting Program Across Seigneurie, Bardy, Blanchette and Sabot Properties
- Carbonatite Boulders and Pegmatite Zones Identified
- 262
Electromed Posts 17% Gain in Fiscal Q4
Electromed (NYSEMKT:ELMD), a medical device company specializing in airway clearance therapy, reported record financial results for the quarter and fiscal year ended August 26, 2025. The company’s
Clene Posts 70% Revenue Drop in Q2
Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important